CytoMed Therapeutics Ltd
GDTC
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.49M
Close$
$-1.25
209.4% downside
Current Fair Value
209.4% downsideOvervalued by 209.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.49 Million |
|---|---|
| Enterprise Value | $12.06 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.33 |
| Beta | -0.04 |
| Outstanding Shares | 11,788,742 |
Return
| Return on Equity | -63.27% |
|---|---|
| Return on Assets | -51.86% |
| Return on Invested Capital | -63.32% |
Valuation & Multiples
| P/E Ratio | -3.16 |
|---|---|
| PEG | -12.66 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 31.02 |
| Enterprise Value to EBIT | -2.62 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 4, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data